Kura Oncology, Inc. — Form 10-Q Summary
Business Context and Reporting Period
Kura Oncology is a clinical-stage biopharmaceutical company developing precision oncology medicines. Its principal clinical programs are tipifarnib, evaluated in genetically defined solid tumors and hematologic malignancies, and KO-539, an oral menin-KMT2A inhibitor being developed for relapsed or refractory acute myeloid leukemia. The filing covers the three months ended March 31, 2021, and was filed May 6, 2021.
Financial Performance and Liquidity
| Metric | Q1 2021 | Q1 2020 | Change |
|---|---|---|---|
| Product revenue | None | None | No approved products or product sales |
| Research and development expense | $20.3 million | $12.6 million | +$7.7 million |
| General and administrative expense | $10.6 million | $7.6 million | +$2.9 million |
| Total operating expenses | $30.9 million | $20.2 million | +$10.7 million |
| Other income, net | $0.2 million | $1.0 million | -$0.8 million |
| Net loss | $30.7 million | $19.2 million | Loss increased $11.5 million |
| Net loss per share | $0.46 | $0.42 | Loss per share increased |
| Cash used in operating activities | $28.5 million | $19.8 million | Use increased $8.7 million |
Cash, cash equivalents and short-term investments totaled $603.9 million at March 31, 2021, compared with $633.3 million at December 31, 2020. Cash and cash equivalents were $110.8 million and short-term investments were $493.0 million. The company reported no product revenue; therefore, revenue-based margins are not meaningful. Share-based compensation expense was $5.1 million, compared with $3.2 million in the prior-year quarter.
Total assets were $620.3 million and total liabilities were $34.3 million at March 31, 2021. Debt consisted of $6.5 million of term debt, including $3.0 million current and $3.5 million long-term. The company repaid $0.8 million of long-term debt during the quarter. It also had $7.3 million of operating lease liabilities.
Investing activities used $186.2 million, primarily because the company purchased $223.2 million of marketable securities and received $37.0 million from maturities. Financing activities provided $0.1 million, consisting primarily of $0.8 million from stock-option exercises, offset by $0.8 million of debt repayment.
Material Changes Versus the Prior Comparable Period
- Research and development expense increased 62%, driven primarily by higher tipifarnib clinical, companion-diagnostic and patient-screening costs, higher KO-539 trial and manufacturing-development costs, and increased personnel expenses.
- Tipifarnib-related research and development costs increased to $10.2 million from $5.8 million; KO-539-related costs increased to $2.7 million from $0.9 million.
- KO-947-related costs declined to $0.1 million from $0.8 million following termination of that ERK inhibitor program in May 2020.
- General and administrative expense increased 39%, primarily due to higher personnel costs and $1.7 million of additional non-cash share-based compensation, partly offset by lower pre-commercial planning expenses.
- Interest income declined to $0.3 million from $1.1 million, reducing other income.
- Operating cash burn increased by $8.7 million, while purchases of marketable securities increased substantially compared with Q1 2020.
- The company began issuing restricted stock units during Q1 2021.
Guidance, Outlook, Risks, and Unusual Items
- Management expects existing cash, cash equivalents and short-term investments to fund operating expenses and capital requirements into 2024, based on current plans.
- Management expects research and development and general and administrative expenses to increase as clinical development and related support activities expand.
- The AIM-HN tipifarnib trial was amended to broaden enrollment to patients with any HRAS mutation and to increase the number of evaluable patients. COVID-19 and the larger enrollment requirement are expected to delay timelines, and the company cannot reasonably forecast when the trial will be fully enrolled.
- Tipifarnib received FDA Breakthrough Therapy Designation in February 2021 for recurrent or metastatic HRAS-mutant head and neck squamous cell carcinoma with variant allele frequency of at least 20% after platinum-based chemotherapy. The designation does not assure approval or a faster development process.
- The company planned to begin a Phase 1/2 study of tipifarnib combined with a PI3 kinase alpha inhibitor in the second half of 2021.
- KO-539’s KOMET-001 trial was amended to add two genetically enriched Phase 1b expansion cohorts for NPM1-mutant and KMT2A-rearranged AML patients, with enrollment expected to begin in mid-2021.
- Key risks include clinical-trial delays or failure, patient enrollment and biomarker-screening challenges, adverse events, dependence on contract research organizations and manufacturers, companion-diagnostic development, regulatory approval uncertainty, intellectual-property limitations, competition, COVID-19 disruption, and the need for substantial additional capital.
- The company has an available $75.0 million at-the-market equity facility but had not sold shares under it as of March 31, 2021. It has no committed external source of additional funding.
- The filing states that there were no material legal proceedings, no material changes in contractual obligations, and no off-balance-sheet arrangements.
Investor Verification Items
- Verify enrollment progress, data quality, and timing for the AIM-HN trial, including the impact of COVID-19 and expanded eligibility.
- Track KO-539 Phase 1b expansion enrollment, safety, efficacy, and the recommended Phase 2 dose.
- Assess whether the projected cash runway into 2024 remains valid as trial scope, enrollment, manufacturing, and regulatory costs evolve.
- Monitor quarterly operating cash burn, short-term investment balances, debt repayments, and any use of the ATM facility or other financing.
- Evaluate whether tipifarnib and KO-539 clinical results support regulatory filings and whether companion diagnostics can be validated and approved.
- Review dilution exposure from the ATM facility, outstanding options, restricted stock units, employee plans, and the outstanding warrant.